Swiss National Bank Acquires 67,240 Shares of Stryker Corporation $SYK

Swiss National Bank grew its stake in shares of Stryker Corporation (NYSE:SYK) by 7.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,010,100 shares of the medical technology company’s stock after purchasing an additional 67,240 shares during the quarter. Swiss National Bank’s holdings in Stryker were worth $331,909,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in SYK. Godfrey Financial Associates Inc. purchased a new position in Stryker in the 4th quarter worth about $26,000. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in Stryker in the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG purchased a new position in shares of Stryker during the fourth quarter worth approximately $28,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Shares of SYK opened at $319.78 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a 50 day moving average price of $312.69 and a 200-day moving average price of $336.82. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock has a market capitalization of $122.59 billion, a PE ratio of 37.01, a PEG ratio of 2.05 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Ratings Changes

Several research firms have recently weighed in on SYK. Wells Fargo & Company decreased their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. BTIG Research set a $371.00 target price on Stryker in a research report on Monday, July 13th. Canaccord Genuity Group lowered their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.